Posterorotación del plano oclusal (TADs): Optimización en Cirugía Ortognática Bimaxilar / No disponible

Los microtornillos (TAD’s) están definitivamente revolucionando el plano vertical de nuestra especialidad. Presentamos un caso diagnosticado como clase II esquelética de causa mandibular en patrón dolicofacial con el plano oclusal rotado en sentido antihorario donde se posteroroto el mismo con dos microtornillos colocados en el borde infra cigomático para a continuación realizar un avance mandibular ambulatorio con anestesia local y sedación consciente. La morbilidad asociada a este procedimiento es mínima en relación a la cirugía ortognatica bimaxilar alternativa (osteotomia segmentaria del maxilar con imputación posterior y osteotomia sagital de rama con avance y antero rotación mandibular) de carácter hospitalario y con anestesia general (AU)

Miniscrews (TAD´s) are definitively revolutionizing the vertical plane in our profession. We present a case diagnosed as a skeletal class II in a dolico facial pattern with a counter clockwise rotated oclusal plane where we rotated it with the use of two minis crews located in the infrazygomatic crest, followed by mandibular advancement surgery under local anesthesia and intravenous sedation. The morbidity associated with this procedure is minimalin relation to an alternative bimaxillary orthognathic surgery procedure (maxillary segmentation with posterior impaction and sagittal ramus osteotomy with advancement and counter clockwise rotation of the mandible) needing hospitalization and general anesthesia (AU)

Hiperqueratosis nevoide del pezón y la areola unilateral tratada con calcitriol tópico / Unilateral Nevoid Hyperkeratosis of the Nipple and Areola Treated With Topical Calcitriol

No disponible

No disponible

Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus.

OBJECTIVES: To determine the safety and efficacy of pimecrolimus cream on lesions of discoid lupus erythematosus. METHODS: In an open-label phase II trial, patients with discoid lupus were treated with pimecrolimus 1% cream twice daily for 8 weeks. We assessed skin involvement with a clinical severity score, quality of life, patient improvement and toxicity. The changes were documented by skin biopsy at baseline and at the end of treatment. RESULTS: Ten patients with a mean age of 34 +/- 17 yr and disease duration of 3 yr (range 1-8) were studied; 90% were female and 40% had received prior topical or systemic therapy without response. In all patients, improvement of skin damage was observed after therapy. A significant decrease of 52% was observed in the mean +/- s.d. clinical severity score, from 6.1 +/- 1.4 before treatment to 2.9 +/- 1.5 after treatment (P = 0.005). Quality of life score (0 = no effect, 100 = maximum effect on quality of life) showed a mean improvement of 46%, from 42.8 +/- 23.1 before to 23 +/- 16.5 after treatment (P = 0.008). According to the patients' assessment of the response to treatment, 50% qualified as marked improvement, 40% moderate and 10% slight improvement. The treatment was well tolerated; adverse reactions consisted of minimal erythema and pruritus, which resolved without any further action. CONCLUSIONS: Our data suggest that pimecrolimus cream for discoid lupus erythematosus seems to be a safe and clinically effective option. However, this was an open and uncontrolled study, and double-blind, placebo-controlled studies are needed.

Acquired ichthyosis associated with systemic lupus erythematosus.

Acquired ichthyosis is an uncommon disease, it is characterized by symmetric scaling of the skin, which ranges from minor roughness and dryness to the desquamation of large plaques. It has been associated with various systemic diseases, although malignant conditions, especially Hodgkin's lymphoma are the most commonly cited. Drugs, HIV infection and autoimmune diseases such as dermatomyositis and mixed connective tissue disease have also been associated, and it has only rarely been found among patients with systemic lupus erythematosus (SLE). Herein, we report a patient with active SLE who developed a generalized acquired ichthyosis corroborated with skin biopsy, which completely disappeared after treatment. The association of autoimmune conditions with acquired ichthyosis could indicate that an abnormal host immune response, probably against components of the granular cell layer in particular the keratohyalin granules, may have a role in the pathogenesis. Thus, this finding may be a relevant cutaneous marker for an autoimmune origin.

Leflunomide in the treatment of psoriasis: results of a phase II open trial.

BACKGROUND: Psoriasis is recognized as the most prevalent T-cell-mediated inflammatory disease in humans, with predominantly activated T-helper (Th) 1 cell effectors. Leflunomide exerts its anti-inflammatory activities by preventing the generation of proinflammatory Th1 effectors and promoting Th2 cell differentiation. OBJECTIVES: To determine the safety and efficacy of leflunomide in patients with moderate to severe plaque-type psoriasis. METHODS: In an open-label phase II trial, eight patients with psoriasis received oral leflunomide 20 mg daily for 12 weeks. Patients were evaluated for improvement in psoriasis, quality of life, histological changes and toxicity. RESULTS: Antipsoriatic effects were obtained in all but two patients. A significant decrease was observed in the mean +/- SD Psoriasis Area and Severity Index score, from 20.08 +/- 6.85 before treatment to 12.51 +/- 11.83 after (P = 0.03). The antipsoriatic efficiency was confirmed histologically, with a significant mean +/- SD decrease in epidermal thickness, from 0.73 +/- 0.19 micro m before to 0.31 +/- 0.16 microm after (P = 0.01). The quality of life score showed an improvement, from 8.58 +/- 2.38 (mean +/- SD) before to 5.33 +/- 1.95 after (P = 0.02). The treatment was well tolerated; adverse reactions primarily consisted of transitory gastrointestinal events. CONCLUSIONS: Our data suggest that leflunomide for plaque-type psoriasis is a safe and clinically effective option as monotherapy. However, double-blind, placebo-controlled studies are needed.

Minor salivary gland punch biopsy for evaluation of Sjögren's syndrome.

Incisional biopsy of labial salivary glands has been a valuable technique for diagnosis of Sjögren's syndrome. This report describes a new technique using punch biopsies that requires fewer resources and appears to be equally effective. Fifty patients evaluated by punch biopsy all yielded adequate pieces averaging 6 glands per specimen. Two patients had transient numbness of the lip. There were no other complications. Classical findings of Sjögren's histopathology were demonstrable with these specimens. This technique is safe, less expensive, and is proposed as a reliable alternative to incisional biopsy.

Factitious disorders mimicking systemic lupus erythematosus.

Factitious disorders are one of the most difficult challenges to the sagacity of the physician. Self-inflicted injuries and diseases have been recognized since Biblical times. In the Middle Ages, hysterics were known to place leeches in their mouths to simulate hemoptysis and to abrade their skin to reproduce skin conditions. Münchausen syndrome, originally described in 1951, is the term applied to persons who seek medical care by feigning illness in the absence of any organic medical or surgical disease. Since the first report of the syndrome, many case reports have documented the performance of unneeded operations and the administration of dangerous drugs to these patients. Rheumatologic manifestations in this syndrome are rare, and include septic arthritis, osteomyelitis, destructive arthropathy, reflex sympathetic dystrophy and systemic lupus erythematosus (SLE). We reviewed the English literature for the past 29 years and found only 8 patients with Münchausen syndrome who simulated SLE. It is interesting to consider the damage mechanisms (some of the patients satisfied 4 or more of the criteria for the classification of SLE) and how a complex disease with a broad spectrum of manifestations such as lupus can be simulated, the only limits being the patient's knowledge and imagination.

[Munchausen's syndrome: a diagnostic challenge]. / Síndrome de Munchausen: reto al diagnóstico.

The Munchausen's syndrome is a variant of chronic factitious illness with predominantly physical signs and symptoms under the conscious control of the patient without any obvious gain. The disorder has also been called hospital addiction, professional patient syndrome and in the field of dermatology, dermatitis artefacta. Munchausen's syndrome may mimic many different conditions, especially acute abdominal pain, hemorrhagic disorders, rheumatologic manifestations, factitious fever, and injury of skin. We describe a 28-year-old woman, who was admitted at a local teaching hospital and studied during three years with complaints of a bleeding ulcer on the left knee, severe enough to require blood transfusions. Many procedures and tests were performed without pathologic findings. Afterward, she was seen at our institution; during the study, the suspicion had arisen that the patient had manipulated her ulcer, after the diagnosis of factitious disease was communicated, she admitted. Munchausen's syndrome may have a broad spectrum of manifestations; early recognition can avoid unnecessary treatments and invasive diagnostic studies, with their inherent risk of complications.